Welcome to DrugBank 4.0! If you prefer, you can still go back to version 3.0.
Identification
NameCyproterone acetate
Accession NumberDB04839
Typesmall molecule
Groupsapproved, investigational
Description

An anti-androgen that, in the form of its acetate (cyproterone acetate), also has progestational properties. It is used in the treatment of hypersexuality in males, as a palliative in prostatic carcinoma, and, in combination with estrogen, for the therapy of severe acne and hirsutism in females. [Pubchem]

Structure
Thumb
Synonyms
SynonymLanguageCode
Cyproterone 17-O-acetateNot AvailableNot Available
SaltsNot Available
Brand names
NameCompany
AndrocurNot Available
CyprostatNot Available
Brand mixtures
Brand NameIngredients
Diane-35Cyproterone Acetate + Ethinyl Estradiol
CategoriesNot Available
CAS number427-51-0
WeightAverage: 416.938
Monoisotopic: 416.175437123
Chemical FormulaC24H29ClO4
InChI KeyInChIKey=UWFYSQMTEOIJJG-HEULQOMWNA-N
InChI
InChI=1/C24H29ClO4/c1-12(26)24(29-13(2)27)8-6-16-14-10-20(25)19-11-21(28)15-9-18(15)23(19,4)17(14)5-7-22(16,24)3/h10-11,14-18H,5-9H2,1-4H3/t14-,15+,16-,17-,18-,22-,23-,24-/s2
IUPAC Name
(1S,2S,3S,5R,11R,12S,15R,16S)-15-acetyl-9-chloro-2,16-dimethyl-6-oxopentacyclo[9.7.0.0²,⁸.0³,⁵.0¹²,¹⁶]octadeca-7,9-dien-15-yl acetate
SMILES
[H][C@@]12C[C@]1([H])[C@@]1(C)C(=CC2=O)C(Cl)=C[C@@]2([H])[C@]3([H])CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@]12[H]
Mass SpecNot Available
Taxonomy
KingdomOrganic Compounds
SuperclassLipids
ClassSteroids and Steroid Derivatives
SubclassGluco/mineralocorticoids, Progestogins and Derivatives
Direct parentGluco/mineralocorticoids, Progestogins and Derivatives
Alternative parentsKetosteroids; Halogenated Steroids; Hydroxysteroids; Tropones; Tertiary Alcohols; Ketones; Cyclic Alcohols and Derivatives; Polyamines; Enolates; Organochlorides
Substituents6-halo-steroid; 3-keto-steroid; 17-hydroxy-steroid; 20-keto-steroid; tropone; cyclic alcohol; tertiary alcohol; ketone; polyamine; enolate; organochloride; organohalogen; alcohol; carbonyl group
Classification descriptionThis compound belongs to the gluco/mineralocorticoids, progestogins and derivatives. These are steroids whose structure is based on an hydroxylated prostane moiety.
Pharmacology
IndicationFor the palliative treatment of patients with advanced prostatic carcinoma.
PharmacodynamicsCyproterone is an antiandrogen. It suppresses the actions of testosterone (and its metabolite dihydrotestosterone) on tissues. It acts by blocking androgen receptors which prevents androgens from binding to them and suppresses luteinizing hormone (which in turn reduces testosterone levels).
Mechanism of actionThe direct antiandrogenic effect of cyproterone is blockage of the binding of dihydrotestosterone to the specific receptors in the prostatic carcinoma cell. In addition, cyproterone exerts a negative feed-back on the hypothalamo-pituitary axis, by inhibiting the secretion of luteinizing hormone resulting in diminished production of testicular testosterone.
AbsorptionCompletely absorbed following oral administration.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Primarily hepatic. Cyproterone acetate is metabolized by the CYP3A4 enzyme, forming the active metabolite 15beta-hydroxycyproterone acetate, which retains its antiandrogen activity, but has reduced progestational activity.

SubstrateEnzymesProduct
Cyproterone acetate
    15beta-hydroxycyproterone acetateDetails
    Route of eliminationIt is excreted approximately 60% in the bile and 33% through the kidneys.
    Half lifeElimination Following oral or intramuscular administration, the plasma half-life is 38 and 96 hours, respectively.
    ClearanceNot Available
    ToxicityNot Available
    Affected organisms
    • Humans and other mammals
    PathwaysNot Available
    SNP Mediated EffectsNot Available
    SNP Mediated Adverse Drug ReactionsNot Available
    ADMET
    Predicted ADMET features
    Property Value Probability
    Human Intestinal Absorption + 1.0
    Blood Brain Barrier + 0.9673
    Caco-2 permeable + 0.7033
    P-glycoprotein substrate Substrate 0.7292
    P-glycoprotein inhibitor I Inhibitor 0.5265
    P-glycoprotein inhibitor II Non-inhibitor 0.9016
    Renal organic cation transporter Non-inhibitor 0.8036
    CYP450 2C9 substrate Non-substrate 0.8
    CYP450 2D6 substrate Non-substrate 0.9116
    CYP450 3A4 substrate Substrate 0.7834
    CYP450 1A2 substrate Non-inhibitor 0.8944
    CYP450 2C9 substrate Non-inhibitor 0.7229
    CYP450 2D6 substrate Non-inhibitor 0.8951
    CYP450 2C19 substrate Non-inhibitor 0.737
    CYP450 3A4 substrate Non-inhibitor 0.8309
    CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8919
    Ames test Non AMES toxic 0.7067
    Carcinogenicity Non-carcinogens 0.926
    Biodegradation Not ready biodegradable 1.0
    Rat acute toxicity 1.8261 LD50, mol/kg Not applicable
    hERG inhibition (predictor I) Weak inhibitor 0.9704
    hERG inhibition (predictor II) Non-inhibitor 0.6939
    Pharmacoeconomics
    ManufacturersNot Available
    PackagersNot Available
    Dosage forms
    FormRouteStrength
    LiquidIntramuscular
    TabletOral
    PricesNot Available
    PatentsNot Available
    Properties
    Statesolid
    Experimental PropertiesNot Available
    Predicted Properties
    PropertyValueSource
    water solubility1.52e-03 g/lALOGPS
    logP3.81ALOGPS
    logP3.64ChemAxon
    logS-5.4ALOGPS
    pKa (strongest acidic)17.83ChemAxon
    pKa (strongest basic)-5.6ChemAxon
    physiological charge0ChemAxon
    hydrogen acceptor count3ChemAxon
    hydrogen donor count0ChemAxon
    polar surface area60.44ChemAxon
    rotatable bond count3ChemAxon
    refractivity111.81ChemAxon
    polarizability44.65ChemAxon
    number of rings5ChemAxon
    bioavailability1ChemAxon
    rule of fiveYesChemAxon
    Ghose filterYesChemAxon
    Veber's ruleNoChemAxon
    MDDR-like ruleNoChemAxon
    Spectra
    SpectraNot Available
    References
    Synthesis Reference

    Aranya Manosroi, “Synthesis of cyproterone acetate.” U.S. Patent US20040024230, issued February 05, 2004.

    US20040024230
    General Reference
    1. Giorgi EP, Shirley IM, Grant JK, Stewart JC: Androgen dynamics in vitro in the human prostate gland. Effect of cyproterone and cyproterone acetate. Biochem J. 1973 Mar;132(3):465-74. Pubmed
    2. Pham-Huu-Trung MT, de Smitter N, Bogyo A, Girard F: Effects of cyproterone acetate on adrenal steroidogenesis in vitro. Horm Res. 1984;20(2):108-15. Pubmed
    3. Stadtler FA, Langner V: The effect of cyproterone and gonadotrophins on the adrenal gland of juvenile and adult rats. A morphological and morphometrical study. Pathol Res Pract. 1985 Mar;179(4-5):493-8. Pubmed
    4. Honer C, Nam K, Fink C, Marshall P, Ksander G, Chatelain RE, Cornell W, Steele R, Schweitzer R, Schumacher C: Glucocorticoid receptor antagonism by cyproterone acetate and RU486. Mol Pharmacol. 2003 May;63(5):1012-20. Pubmed
    5. Holdaway IM, Croxson MS, Evans MC, France J, Sheehan A, Wilson T, Ibbertson HK: Effect of cyproterone acetate on glucocorticoid secretion in patients treated for hirsutism. Acta Endocrinol (Copenh). 1983 Oct;104(2):222-6. Pubmed
    External Links
    ResourceLink
    ChEBI50743
    ChEMBLCHEMBL142130
    Therapeutic Targets DatabaseDAP000906
    PharmGKBPA10049
    Drug Product Database704423
    WikipediaCyproterone_acetate
    ATC CodesG03HA01
    AHFS CodesNot Available
    PDB EntriesNot Available
    FDA labelNot Available
    MSDSNot Available
    Interactions
    Drug InteractionsNot Available
    Food InteractionsNot Available

    1. Androgen receptor

    Kind: protein

    Organism: Human

    Pharmacological action: yes

    Actions: antagonist

    Components

    Name UniProt ID Details
    Androgen receptor P10275 Details

    References:

    1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
    2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
    3. Agoulnik IU, Weigel NL: Coactivator selective regulation of androgen receptor activity. Steroids. 2009 Aug;74(8):669-74. Epub 2009 Mar 9. Pubmed
    4. Cabeza M, Flores M, Bratoeff E, de la Pena A, Mendez E, Ceballos G: Intracellular Ca2+ stimulates the binding to androgen receptors in platelets. Steroids. 2004 Oct-Nov;69(11-12):767-72. Pubmed
    5. Sonneveld E, Jansen HJ, Riteco JA, Brouwer A, van der Burg B: Development of androgen- and estrogen-responsive bioassays, members of a panel of human cell line-based highly selective steroid-responsive bioassays. Toxicol Sci. 2005 Jan;83(1):136-48. Epub 2004 Oct 13. Pubmed

    1. Cytochrome P450 19A1

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: inhibitor

    Components

    Name UniProt ID Details
    Cytochrome P450 19A1 P11511 Details

    References:

    1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

    Comments
    Drug created on September 26, 2007 09:23 / Updated on March 11, 2014 09:26